Respiratory Disease Vaccine Market Size & Forecast to 2032

The Respiratory Disease Vaccine Market is projected to reach USD 64.80 Billion in 2026. It is expected to continue growing at a CAGR of 5.71%, reaching USD 91.67 Billion by 2032.

Respiratory disease vaccines are moving from seasonal public-health tools to a core pillar of global immunization strategy. The landscape spans influenza vaccines, COVID-19 vaccines, respiratory syncytial virus (RSV) vaccines, pneumococcal vaccines, pertussis-containing vaccines, and emerging candidates designed to broaden protection against severe respiratory infections. Demand is supported by well-documented disease burden: the WHO recognizes lower respiratory infections as a leading global cause of mortality, while CDC surveillance continues to show meaningful hospitalization risk from influenza, COVID-19, and RSV, particularly among infants, older adults, pregnant people, and immunocompromised populations.

The industry is being shaped by platform diversification, including egg-based, cell-based, recombinant, viral-vector, protein subunit, conjugate, and mRNA technologies. Regulatory agencies have also expanded vaccine pathways for respiratory disease prevention, most notably through updated COVID-19 strain selection, adult RSV vaccine approvals, maternal immunization strategies, and pediatric monoclonal antibody programs that complement vaccine-based prevention.

For manufacturers, healthcare systems, and investors, the respiratory disease vaccine landscape is increasingly defined by speed, durability of protection, strain-matching accuracy, cold-chain resilience, and equitable access. Competitive advantage is shifting toward organizations that can integrate surveillance data, platform agility, real-world effectiveness evidence, and scalable manufacturing into a unified respiratory vaccine portfolio.

Transformative Shifts in the Respiratory Vaccine Landscape

The respiratory disease vaccine landscape is undergoing a structural transformation driven by the convergence of endemic COVID-19 management, RSV prevention, influenza modernization, and adult immunization expansion. Seasonal vaccine planning is no longer limited to influenza; public-health agencies now evaluate co-circulation of influenza viruses, SARS-CoV-2 variants, RSV, and pneumococcal disease when designing vaccination recommendations and healthcare capacity plans.

One of the most important shifts is the rise of adult respiratory immunization. RSV vaccines for older adults and maternal RSV vaccination have expanded the public-health relevance of respiratory vaccines beyond traditional pediatric and influenza programs. At the same time, updated COVID-19 vaccines have normalized strain-updated vaccination cycles and accelerated public understanding of platform-based vaccine development.

Manufacturing strategy is also changing. Egg-based influenza production remains important, but cell-based, recombinant, and mRNA platforms are gaining attention because they can reduce dependence on egg-adapted viral changes and support faster strain updates. The next phase of competition will depend on improving vaccine effectiveness, broadening protection across variants and age groups, and reducing operational complexity for immunization providers.

Cumulative Impact of Artificial Intelligence on Vaccine Innovation

Artificial intelligence is having a cumulative impact across respiratory vaccine discovery, development, manufacturing, and post-market monitoring. In antigen discovery, AI-enabled protein modeling, epitope prediction, and immune-response simulations help researchers prioritize vaccine targets for pathogens such as influenza, SARS-CoV-2, RSV, and pneumococcus. These approaches do not replace clinical validation, but they can shorten early-stage screening and improve the selection of candidates with stronger immunogenicity potential.

AI is also strengthening epidemiological intelligence. Machine-learning models are increasingly used to analyze genomic surveillance, mobility patterns, wastewater signals, electronic health records, and laboratory reporting to identify shifts in viral circulation. For vaccine manufacturers and public-health agencies, these tools can support strain-selection decisions and distribution planning, especially during periods of co-circulating respiratory pathogens.

In clinical development and pharmacovigilance, AI can improve trial-site selection, identify underrepresented populations, monitor safety signals, and analyze real-world vaccine effectiveness. Industry leaders must pair AI adoption with transparent model governance, validated datasets, cybersecurity controls, and regulatory-grade documentation to ensure that AI-generated insights are reliable, auditable, and clinically meaningful.

Key Regional Insights Across Global Respiratory Vaccine Markets

Asia-Pacific is a high-priority region because it combines large birth cohorts, aging populations, dense urban centers, and significant seasonal respiratory disease burden. China, India, Japan, South Korea, and Australia are central to regional vaccine demand, with policy attention focused on influenza, COVID-19, pneumococcal disease, pertussis, and RSV prevention. The region also plays a major role in vaccine manufacturing and clinical research, supported by expanding biotechnology capacity and government-backed immunization programs.

North America remains one of the most advanced respiratory vaccine markets, supported by CDC and Health Canada recommendations, high regulatory clarity, strong pharmacy-based vaccination channels, and rapid integration of newly approved adult RSV and updated COVID-19 vaccines into immunization guidance. The United States leads in innovation financing and commercialization infrastructure, while Canada emphasizes publicly funded immunization strategies and national advisory guidance.

Latin America shows rising strategic relevance as countries strengthen adult vaccination, respiratory virus surveillance, and pandemic preparedness, with Brazil and Mexico serving as important anchors for public immunization programs and regional procurement. Europe benefits from mature regulatory systems, centralized scientific evaluation through the European Medicines Agency, and coordinated disease surveillance through European public-health networks. The Middle East is investing in preventive healthcare, digital health, and cold-chain modernization, particularly across Gulf economies. Africa remains a critical access region where respiratory vaccine priorities intersect with childhood immunization, donor-supported procurement, local manufacturing initiatives, and health-system strengthening.

Key Group Insights for Strategic Vaccine Planning

ASEAN markets are increasingly important for respiratory disease vaccine planning because of large populations, cross-border mobility, tropical and subtropical influenza circulation patterns, and expanding national immunization infrastructure. Regional priorities include improving influenza vaccine access, sustaining COVID-19 booster strategies for high-risk groups, and strengthening pediatric respiratory disease prevention. Local fill-finish capacity, public procurement, regional regulatory cooperation, and partnerships with global health stakeholders remain important for supply security.

The GCC is advancing respiratory vaccination through well-funded healthcare systems, digital health platforms, and preventive-care initiatives for older adults, healthcare workers, pilgrims, and people with chronic disease. The European Union provides one of the world’s most structured vaccine environments, combining regulatory harmonization, joint scientific assessment, cross-country safety monitoring, and coordinated disease surveillance. These features support faster evidence generation and consistent evaluation of new respiratory vaccine technologies.

BRICS countries represent a diverse but influential group, combining major vaccine manufacturing capacity, large patient populations, public-sector immunization programs, and growing investments in biotechnology. The G7 remains central to vaccine innovation, funding, regulatory science, genomic surveillance, and pandemic preparedness. NATO countries, while not a vaccine market bloc, are relevant because health security, supply-chain resilience, biological preparedness, and medical countermeasure readiness have become strategic priorities for allied governments.

Key Country Insights Shaping Respiratory Vaccine Demand

The United States is the leading innovation and commercialization environment for respiratory disease vaccines, supported by FDA regulatory pathways, CDC recommendations, pharmacy access, immunization registries, and strong public-private research funding. Canada follows evidence-based national advisory processes and emphasizes equitable access across provinces and territories. Mexico and Brazil are major Latin American markets where public immunization programs, respiratory disease surveillance, domestic manufacturing partnerships, and centralized procurement mechanisms shape vaccine access and adoption.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are mature vaccine markets with strong clinical guidance, established reimbursement mechanisms, and growing attention to adult RSV, influenza, pneumococcal, pertussis-containing, and COVID-19 vaccination. Russia maintains domestic vaccine production capabilities and a large population base, although geopolitical factors can affect international collaboration, regulatory alignment, and supply dynamics.

China and India are pivotal because of their population scale, manufacturing capacity, expanding biotechnology sectors, and national focus on infectious disease preparedness. Japan has one of the world’s most aging populations, making adult respiratory vaccination particularly important for reducing severe illness and healthcare burden. Australia has a strong immunization registry, seasonal influenza programs, and risk-based vaccination guidance, while South Korea combines advanced biomanufacturing, digital health infrastructure, and active vaccine R&D to strengthen its role in the Asia-Pacific respiratory vaccine landscape.

Actionable Recommendations for Respiratory Vaccine Leaders

Industry leaders should prioritize portfolio strategies that address the full respiratory disease continuum, including influenza, COVID-19, RSV, pneumococcal disease, pertussis, and combination vaccine opportunities. Organizations that can simplify immunization schedules, reduce clinic burden, and demonstrate real-world effectiveness across high-risk groups will be better positioned with regulators, payers, and public-health buyers.

Manufacturers should invest in flexible platforms such as mRNA, recombinant protein, cell-based production, conjugate technologies, and advanced adjuvant systems while maintaining resilient supply for proven vaccine technologies. Strategic partnerships with surveillance networks, academic centers, contract manufacturers, and regional fill-finish providers can improve responsiveness during seasonal surges and emerging variant threats.

Commercial teams should build evidence packages around hospitalization reduction, durability of protection, safety in older adults, maternal and infant outcomes, coadministration feasibility, and health-economic value. Digital engagement with providers, pharmacy channels, and public-health systems can improve uptake, but messaging must be transparent, science-led, and designed to rebuild vaccine confidence in populations affected by misinformation.

Research Methodology for Evidence-Based Industry Analysis

This executive summary is developed using a structured secondary-research approach grounded in publicly available and scientifically credible sources. Inputs include guidance and surveillance from the WHO, CDC, FDA, European Medicines Agency, European Centre for Disease Prevention and Control, national immunization advisory bodies, peer-reviewed journals, regulatory filings, and public-health datasets related to influenza, COVID-19, RSV, pneumococcal disease, pertussis, and other respiratory infections.

The methodology emphasizes triangulation across epidemiology, regulatory activity, vaccine technology trends, immunization policy, manufacturing capacity, and regional access dynamics. Interpretation is based on verified indicators such as disease burden, approval pathways, vaccination recommendations, demographic risk factors, public procurement structures, and observed shifts in respiratory virus circulation.

All insights are screened for relevance to the respiratory disease vaccine industry and presented in a forward-looking executive format. Where quantitative claims vary by source, the analysis favors consensus findings from recognized public-health authorities and avoids unsupported projections, unverified commercial assumptions, market sizing, market share, or forecasting.

Conclusion: Building the Future of Respiratory Disease Prevention

The respiratory disease vaccine landscape is entering a more complex and strategically important phase. Influenza vaccination remains foundational, COVID-19 has established a recurring need for updated immunization, RSV vaccines have opened a major adult and maternal prevention category, and pneumococcal vaccines continue to play a critical role in reducing severe respiratory complications.

Future leadership will depend on platform agility, strong safety evidence, real-world effectiveness, equitable access, and the ability to align innovation with public-health priorities. Artificial intelligence, genomic surveillance, and advanced manufacturing can accelerate progress, but success will require rigorous validation, transparent communication, and sustained trust among healthcare providers and patients.

For stakeholders across the value chain, respiratory disease vaccines should be viewed not as isolated seasonal products but as an integrated prevention ecosystem. Organizations that combine scientific credibility, regional execution, and resilient supply chains will be best positioned to support long-term growth while improving population health outcomes.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Respiratory Disease Vaccine Market, by Vaccine Type

7.1. Introduction
7.2. Influenza Vaccines
7.3. COVID-19 Vaccines
7.3.1. mRNA Vaccines
7.3.2. Viral Vector Vaccines
7.3.3. Protein Subunit Vaccines
7.3.4. Inactivated Vaccines
7.4. Pneumococcal Vaccines
7.4.1. Pneumococcal Conjugate Vaccines
7.4.2. Pneumococcal Polysaccharide Vaccines
7.5. Respiratory Syncytial Virus Vaccines
7.6. Tuberculosis Vaccines
7.6.1. BCG Vaccines
7.6.2. Recombinant TB Vaccines
7.7. Pertussis Vaccines

8. Respiratory Disease Vaccine Market, by Route Of Administration

8.1. Introduction
8.2. Intramuscular
8.3. Intranasal
8.4. Oral
8.5. Subcutaneous

9. Respiratory Disease Vaccine Market, by Age Group

9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric

10. Respiratory Disease Vaccine Market, by End User

10.1. Introduction
10.2. Clinics
10.3. Home Care
10.4. Hospitals
10.4.1. Government Hospitals
10.4.2. Private Hospitals
10.5. Research Institutes
10.6. Vaccination Centers

11. Respiratory Disease Vaccine Market, by Distribution Channel

11.1. Introduction
11.2. Online Pharmacies
11.3. Offline Pharmacies

12. Respiratory Disease Vaccine Market, by Region

12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa

13. Respiratory Disease Vaccine Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Respiratory Disease Vaccine Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Arcturus Therapeutics Holdings Inc.
16.2. AstraZeneca plc
16.3. Bavarian Nordic A/S
16.4. Bharat Biotech International Limited
16.5. Biological E. Limited
16.6. BioNTech SE
16.7. CanSino Biologics Inc.
16.8. CSL Seqirus
16.9. CureVac N.V.
16.10. Emergent BioSolutions Inc.
16.11. GeoVax Labs, Inc.
16.12. GlaxoSmithKline plc
16.13. Inovio Pharmaceuticals, Inc.
16.14. Meiji Seika Pharma Co., Ltd.
16.15. Merck & Co., Inc.
16.16. Mitsubishi Tanabe Pharma Corporation
16.17. Moderna, Inc.
16.18. Novavax, Inc.
16.19. Panacea Biotec Ltd.
16.20. Pfizer Inc.
16.21. Sanofi
16.22. Serum Institute of India Pvt. Ltd.
16.23. Sinopharm Group Co. Ltd.
16.24. Sinovac Biotech Ltd.
16.25. SK bioscience Co., Ltd.
16.26. Valneva SE
16.27. Vaxart, Inc.
16.28. Vaxcyte, Inc.
16.29. Walvax Biotechnology Co., Ltd.

List of Figures

FIGURE 1. GLOBAL RESPIRATORY DISEASE VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL RESPIRATORY DISEASE VACCINE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL RESPIRATORY DISEASE VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INFLUENZA VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INFLUENZA VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MRNA VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MRNA VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MRNA VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PROTEIN SUBUNIT VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PROTEIN SUBUNIT VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PROTEIN SUBUNIT VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PNEUMOCOCCAL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL PNEUMOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL PNEUMOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PNEUMOCOCCAL CONJUGATE VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PNEUMOCOCCAL CONJUGATE VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PNEUMOCOCCAL CONJUGATE VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL TUBERCULOSIS VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL TUBERCULOSIS VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL TUBERCULOSIS VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL BCG VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL BCG VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL BCG VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL RECOMBINANT TB VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL RECOMBINANT TB VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL RECOMBINANT TB VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL PERTUSSIS VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL PERTUSSIS VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL PERTUSSIS VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL INTRANASAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INTRANASAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INTRANASAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL GOVERNMENT HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL GOVERNMENT HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL GOVERNMENT HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL VACCINATION CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL VACCINATION CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL VACCINATION CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 129. EUROPE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. EUROPE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 131. EUROPE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 132. EUROPE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 133. EUROPE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 134. EUROPE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 135. EUROPE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 136. EUROPE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 137. EUROPE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 138. EUROPE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 143. MIDDLE EAST RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 144. MIDDLE EAST RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 149. AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 150. AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 151. AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 152. AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 153. AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 154. AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 155. AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 156. AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 158. AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. ASEAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. ASEAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 162. ASEAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 163. ASEAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 164. ASEAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 165. ASEAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 166. ASEAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 167. ASEAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. ASEAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 169. ASEAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 170. GCC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 171. GCC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 172. GCC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 173. GCC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 174. GCC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 175. GCC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 176. GCC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 177. GCC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 178. GCC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 179. GCC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. BRICS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 191. BRICS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 192. BRICS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 193. BRICS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 194. BRICS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 195. BRICS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 196. BRICS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 197. BRICS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 198. BRICS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 199. BRICS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 200. G7 RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 201. G7 RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 202. G7 RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 203. G7 RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 204. G7 RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 205. G7 RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 206. G7 RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 207. G7 RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. G7 RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 209. G7 RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 210. NATO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 211. NATO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 212. NATO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 213. NATO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 214. NATO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 215. NATO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 216. NATO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 217. NATO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. NATO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 219. NATO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 220. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 221. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 222. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 223. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 224. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 225. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 226. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 227. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 228. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 230. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 232. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 233. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 234. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 235. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 236. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 237. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 238. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 239. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 240. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 241. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 242. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 243. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 244. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 245. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 246. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 247. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 248. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 250. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 251. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 252. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 253. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 254. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 255. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 256. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 257. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 258. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 259. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 260. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 262. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 263. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 264. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 265. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 266. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 267. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 268. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 269. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 270. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 271. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 272. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 273. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 274. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 275. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 276. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 277. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 278. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 280. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 281. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 283. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 284. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 285. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 286. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 287. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 288. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 290. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 291. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 292. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 293. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 294. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 295. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 296. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 297. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 298. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 299. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 300. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 301. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 302. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 303. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 304. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 305. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 306. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 307. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 308. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 309. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 310. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 311. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 312. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 313. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 314. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 315. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 316. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 317. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 318. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 319. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 320. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 321. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 322. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 323. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 324. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 325. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 326. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 327. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 328. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 329. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 330. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 331. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 332. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 333. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COVID-19 VACCINES, 2017-2032 (USD MILLION)
TABLE 334. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PNEUMOCOCCAL VACCINES, 2017-2032 (USD MILLION)
TABLE 335. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS VACCINES, 2017-2032 (USD MILLION)
TABLE 336. INDIA RESPIRATORY DISEASE VACCIN

Companies Mentioned

Arcturus Therapeutics Holdings Inc.
AstraZeneca plc
Bavarian Nordic A/S
Bharat Biotech International Limited
Biological E. Limited
BioNTech SE
CanSino Biologics Inc.
CSL Seqirus
CureVac N.V.
Emergent BioSolutions Inc.
GeoVax Labs, Inc.
GlaxoSmithKline plc
Inovio Pharmaceuticals, Inc.
Meiji Seika Pharma Co., Ltd.
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Moderna, Inc.
Novavax, Inc.
Panacea Biotec Ltd.
Pfizer Inc.
Sanofi
Serum Institute of India Pvt. Ltd.
Sinopharm Group Co. Ltd.
Sinovac Biotech Ltd.
SK bioscience Co., Ltd.
Valneva SE
Vaxart, Inc.
Vaxcyte, Inc.
Walvax Biotechnology Co., Ltd.

Table Information

Report Attribute	Details
No. of Pages	197
Published	August 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 64.8 Billion
Forecasted Market Value ( USD ) by 2032	$ 91.67 Billion
Compound Annual Growth Rate	5.7%
Regions Covered	Global
No. of Companies Mentioned	29

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3156EUR$3,545USD£2,712GBP €3507EUR$3,939USD£3,014GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4775EUR$5,363USD£4,103GBP €5306EUR$5,959USD£4,559GBP

Respiratory Disease Vaccine Market - Global Forecast 2026-2032

Transformative Shifts in the Respiratory Vaccine Landscape

Cumulative Impact of Artificial Intelligence on Vaccine Innovation

Key Regional Insights Across Global Respiratory Vaccine Markets

Key Group Insights for Strategic Vaccine Planning

Key Country Insights Shaping Respiratory Vaccine Demand

Actionable Recommendations for Respiratory Vaccine Leaders

Research Methodology for Evidence-Based Industry Analysis

Conclusion: Building the Future of Respiratory Disease Prevention

Table of Contents

Companies Mentioned

Table Information

Transformative Shifts in the Respiratory Vaccine Landscape

Cumulative Impact of Artificial Intelligence on Vaccine Innovation

Key Regional Insights Across Global Respiratory Vaccine Markets

Key Group Insights for Strategic Vaccine Planning

Key Country Insights Shaping Respiratory Vaccine Demand

Actionable Recommendations for Respiratory Vaccine Leaders

Research Methodology for Evidence-Based Industry Analysis

Conclusion: Building the Future of Respiratory Disease Prevention

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Respiratory Disease Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

Respiratory Disease Vaccine Market Report 2026

Respiratory Disease Vaccine Market Outlook 2025-2034: Market Share, and Growth Analysis

Respiratory Disease Vaccines Market - Global Strategic Business Report

Pneumonia Therapeutics Market - Global Forecast 2026-2032

About the Respiratory Disease Vaccine Market